Abstract
There is good evidence that dedicated early arthritis clinics (EACs) improve referral lag time and reduce delay in establishing disease-modifying therapy. However, it remains arguable whether such clinics improve relevant disease outcomes. Nationally, only 57% of units have dedicated EACs. Our rheumatology department established a centralised, patient-focused and multidisciplinary EAC to achieve key financial and clinical outcome targets the department was failing to meet. The EAC aimed to increase the department’s capacity to accommodate referrals from general practitioners (GPs) and other sources, decrease the time between diagnosis and starting therapy, establish standardised treatment algorithms and reduce biologic use. The EAC was established in January 2016 and comprised the introduction of a dedicated referral pro forma and an EA educational programme for GPs, pooling of all sources of referral, running of six EACs per week with availability of ultrasound and introduction of a standardised approach to the early initiation of therapy and timely review of treatment outcomes. The introduction of the EAC was associated with improved clinical outcomes (EA patients achieving a Disease Activity Score 28 (DAS28) < 3.2 in 2015, 38.0% [N = 113] vs. 78.5% [N = 220] in 2016) and overall patient experience (mean waiting time for EA patients’ first appointment in 2015: 12 weeks vs. 2.5 weeks in 2016; 94% [N = 167] of patients recommended the rheumatology service in 2016 vs. 74% [N = 100] in 2015). The total costs associated with introducing the EAC were ~ £201,362. Use of biologics decreased from 26.0 to 5.6% between 2015 and 2016, resulting in a cost saving of ~ £394,942. Other cost savings associated with the EAC included reductions in the overall cost/patient seen (2015, £198.88; 2016, £74.98) and not running any premium rate initiative clinics (saving ~ £26,500 in 2016) to meet waiting list targets. Efficiency gains from the introduction of the EACs have improved patients’ health and overall satisfaction with their treatment, whilst saving costs for healthcare.
References
Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959
National Institute for Health and Care Excellence (2013) Rheumatoid arthritis: NICE quality standard [QS33] https://www.nice.org.uk/guidance/qs33. (accessed 19 Dec 2018)
Emery P, Gough A (1991) Why early arthritis clinics? Br J Rheumatol 30:241–242
BSR National Clinical audit for rheumatoid and early inflammatory arthritis 2nd Annual report 2016 https://www.rheumatology.org.uk/Knowledge/Excellence/Audits/Reports (accessed 19 Dec 2018)
Govoni M, Scire CA, Manara M et al (2013) Does early arthritis clinic organisation improve outcomes? What evidence is there? A systematic review. Clin Exp Rheumatol 31:443–451
Walker-Bone K, Black C (2016) The importance of work participation as an outcome in rheumatology. Rheumatology (Oxford) 55:1345–1347
March L, Lapsley H (2000) What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract Res Clin Rheumatol 15:171–185
Null Dexneuner V, Rezende LS, Stamm TA, Duer M, Smolen JS, Machold KP (2012) Attending and non-attending patients in a real-life setting of an early arthritis clinic: why do people leave clinics and where do they go? Clin Exp Rheumatol 30:184–190
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nisar, M.K. Early arthritis clinic is cost-effective, improves outcomes and reduces biologic use. Clin Rheumatol 38, 1555–1560 (2019). https://doi.org/10.1007/s10067-019-04515-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-019-04515-3